LOGIN

List prices for Medicare negotiation-eligible medicines targeted by Build Back Better drug pricing provisions estimated to be reduced by over 40% on average.

Yearly Archives: 2022

List prices for Medicare negotiation-eligible medicines targeted by Build Back Better drug pricing provisions estimated to be reduced by over 40% on average.

  • 8 June 2022
Read More

Forecasting Drug Price for Reimbursement By Utilizing a Value-Price Relationship, a Case Study in Hormone-Relapsed Prostate Cancer

  • 8 June 2022
Read More

The impact of Value-Based Pricing (VBP) vs International Reference Pricing (IRP) on innovative drugs in the US

  • 1 June 2022
Read More

Biomarker-targeted therapies: the answer to advancing equitable cancer care?

  • By Kate Anstee
  • 1 June 2022
Read More

What should drug pricing reforms look like in the United States?

  • By Margaret Labban, PhD
  • 1 June 2022
Read More
Default Image

The growing call for greater transparency into drug prices Guest writer: Kyle Forcier, Model N

  • 20 May 2022
Read More

Price management solution optimized to reduce manual processing

  • 21 April 2022
Read More

GPI announces major research presence at ISPOR

  • 12 April 2022
Read More
Default Image

FDA deals significant blow to low-priced Chinese oncology drugs

  • 6 April 2022
Read More
Default Image

Women Scientists behind the COVID-19 vaccines

  • 8 March 2022
Read More

Previous Posts Next posts

Stay Informed

Sign up to receive the latest news and trends
straight into your inbox from GPI